Approximately 1 in 10 adults aged ≥60 years received an RSV vaccination during the first season of vaccine availability, with relatively low uptake observed across ages and evaluated risk factors. Previous research has estimated that nearly half of older adults have a diagnosed risk factor for ...
The U.S. Food and Drug Administration on Tuesday approvedPfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease. In June, the U.S. CDCnarrowedits recommendation for the use of respiratory ...
In two other studies, approximately 2,500 participants 60 years of age and older received Arexvy. In one of these studies, in which some participants received Arexvy concomitantly with an FDA-approved influenza vaccine, two participants developed acute disseminated encephalomyelitis (ADEM), ...
and colleagues estimated RSVpreFvaccineeffectiveness in older adults in a retrospective case-control study. Cases were adults aged 60 years or older (mean age, 76.8 years) with hospitalizations or emergency department visits for LRTD from Nov. 24, 2023, to April 9, 2024, who had respiratory...
CDC's Advisory Committee on Immunization Practices recommended a shared decision-making approach between age-eligible adults and their providers for a single dose of either RSVPreF3 (Arexvy, GSK) or RSVpreF (AbrysvoTM, Pfizer) vaccines. We examined uptake among age-eligible Kaiser Permanente ...
The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 and older.
1、FDA NEWS RELEASE FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine Arexvy Approved for Individuals 60 Years of Age and Older 2、 生物制品圈,全球首款!GSK潜在重磅RSV疫苗获FDA批准 3、宋海波:后疫情时期,呼吸道症候群病原体多重检测的重要意义!
The ACIP did not hold a vote on whether to recommend RSV vaccination for patients aged 50 to 59 years despite the FDA’s recent decision to extend the approval of GSK’s vaccine for high-risk patients in that age group. References: ...
Beyfortus is used to protect babies under 1 year of age from serious RSV lung infections. A ... Reviews & ratings Add a review View more mRESVIA mResvia is an RSV vaccine that may be used to protect adults aged 60 years and older against lower ... ...
Last year, the US Food and Drug Administration approved ABRYVSO for use in people aged 60 years or older, but there is no RSV vaccine available for younger adults, even though immunocompromised individuals of any age have an increased risk of RSV complications, Pfizer noted in its news ...